On August 10, 2026, a Phase 3 clinical trial update was recorded for the study titled "A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)," registered as NCT07340827.
The trial is listed with a status of RECRUITING. It is designed to compare Follitropin Alfa/Lutropin Alfa against hMG in Japanese participants with LH and FSH deficiency who are undergoing assisted reproductive technology (ART) procedures.
The study is registered under phase designation Phase 3. No results have been posted for this trial as of the update date. The listing does not include efficacy or safety findings at this stage, as the study remains in the recruiting phase.
Further details on the trial design, eligibility criteria, and protocol can be found on the official ClinicalTrials.gov registry page associated with this study identifier.
Readers interested in background on cetrorelix, including its approved uses and regulatory status, can consult the compound overview for additional context.